Blood pressure medication prazosin hydrochloride has been recalled due to elevated levels of carcinogens.
Teva Pharmaceuticals has voluntarily recalled nearly 581,000 bottles of prazosin hydrochloride capsules after tests found levels of a potential carcinogen above acceptable limits.
The recall, initiated Oct. 7, was classified by the Food and Drug Administration as Class II on Oct. 24, indicating that use or exposure “may cause temporary or medically reversible adverse health consequences,” with a remote probability of serious harm.
Prazosin is a medication prescribed primarily for high blood pressure and prostate conditions and is sometimes used off-label for post-traumatic stress disorder. The FDA said the recalled capsules contain elevated levels of an N-nitroso prazosin impurity.
Products affected
-
1 mg: 181,659 bottles (NDC 0093-4067-01, 0093-4067-10), lots 3010544A, 3010545A, expiring October 2025.
-
2 mg: 291,512 bottles (NDC 0093-4068-01, 0093-4068-10), multiple lots, expirations October 2025–July 2026.
-
5 mg: 107,673 bottles (NDC 0093-4069-01, 0093-4069-52, 0093-4069-05), multiple lots, expirations into 2026.
Teva said customers have been notified by letter and that the recall is ongoing.
What patients should do
Patients taking prazosin should contact their health care provider promptly; abruptly stopping blood pressure medication can be risky. Pharmacists and clinicians can confirm whether a prescription is part of the recall and discuss alternatives.
